InSite eyes Phase III with once-daily eye drug; Canadian scientists develop cancer-targeting nanoparticles;

> InSite Vision, of Alameda, CA, said that it plans to pursue a Phase III trial of ISV-303, its once-daily formulation of the anti-inflammatory drug bromfenac, for treating pain and inflammation after eye surgeries following the promising results of an exploratory Phase I/II study involving 169 patients who underwent cataract surgeries. InSite release

> Echo Therapeutics ($ECTE.OB), a Frankin, MA-based developer of transdermal systems for continuous glucose monitoring and drug delivery, said in its annual report that its net loss dropped from $11 million in fiscal 2009 to $4.1 million in fiscal 2010. Its cash balance as of March 18 was approximately $5.1 million. Echo release

> A team from Ontario Cancer Institute at Princess Margaret Hospital reports the creation of a nanoparticle made with chlorophyll and lipid components that might have use in targeted delivery of cancer drugs and imaging tumors. Story

> Raleigh, NC-based BioDelivery Sciences International ($BDSI) said that that Canada's Office of Patented Medicines has extended its patent on a drug delivery technology from 2017 to 2027. The technology is used for Onsolis, which involves a dissolvable film placed on the inside of the cheek and releases the painkiller fentanyl for cancer patients. Article

> Inovio Pharmaceuticals ($INO), of Blue Bell, PA, reports that it has garnered a U.S. Department of Defense Small Business Innovation Research Grant to "test the feasibility of delivering DNA vaccines by intradermal electroporation simultaneously to two or more spatially distinct sites on the body. Release

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.